This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Allal, A. S. Articles by Slosman, D. O. Search for Related Content PubMed PubMed Citation Articles by Allal, A. S. Articles by Slosman, D. O. Social Bookmarking                            What's this?

Standardized Uptake Value of 2-[¹⁸F] Fluoro-2-Deoxy-D-Glucose in Predicting Outcome in Head and Neck Carcinomas Treated by Radiotherapy With or Without Chemotherapy

From the Divisions of Radiation Oncology, Head and Neck Surgery, and Nuclear Medicine, University Hospital, Geneva, Switzerland.

Address reprint requests to Abdelkarim S. Allal, MD, Radiation Oncology Division, University Hospital, 24 Rue Micheli-du-Crest, 1211 Geneva 14, Switzerland; email: abdelkarim.allal{at}hcuge.ch

PURPOSE: In patients with head and neck cancer enrolled onto a prospective study of positron emission tomography (PET), pretreatment 2-[¹⁸F] fluoro-2- deoxy-D-glucose (FDG) uptake was evaluated as a predictor of local control and disease-free survival (DFS) after treatment by radiotherapy (RT) with or without chemotherapy.

PATIENTS AND METHODS: We studied 63 patients with carcinomas of the head and neck who had an FDG-PET scan before radical RT. Tumor FDG uptake was measured with the semiquantitative standardized uptake value (SUV). All patients but one were treated with accelerated or hyperfractionated RT schedules. Thirteen patients received concomitant cisplatin-based chemotherapy.

RESULTS: In 25 patients who presented with any component of treatment failure, the SUV was significantly higher than in the remaining patients without any such failure. Patients having tumors with high FDG uptake had a significantly lower 3-year local control (55% v 86%, P = .01) and DFS (42% v 79%, P = .005) compared with patients having low uptake tumors. In the multivariate analysis, the only factor that retained its significance for DFS was SUV category, whereas T category was of borderline significance. For local control, T category remained a significant factor, whereas a lower local control was observed for tumors with a high SUV compared with those with low SUV.

CONCLUSION: FDG uptake, as measured by the SUV, has potential value in predicting local control and DFS in head and neck carcinomas treated by RT. High FDG uptake may be a useful parameter for identifying patients requiring more aggressive treatment approaches.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. K. Chung, H.-S. Jeong, S. G. Park, J. Y. Jang, Y.-I. Son, J. Y. Choi, S. H. Hyun, K. Park, M.-J. Ahn, Y. C. Ahn, et al. Metabolic Tumor Volume of [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Short-Term Outcome to Radiotherapy With or Without Chemotherapy in Pharyngeal Cancer Clin. Cancer Res., September 15, 2009; 15(18): 5861 - 5868. [Abstract] [Full Text] [PDF]

				T. B. Bartel, J. Haessler, T. L. Y. Brown, J. D. Shaughnessy Jr, F. van Rhee, E. Anaissie, T. Alpe, E. Angtuaco, R. Walker, J. Epstein, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma Blood, September 3, 2009; 114(10): 2068 - 2076. [Abstract] [Full Text] [PDF]

				T. Torizuka, Y. Tanizaki, T. Kanno, M. Futatsubashi, K. Naitou, Y. Ueda, and Y. Ouchi Prognostic Value of 18F-FDG PET in Patients with Head and Neck Squamous Cell Cancer Am. J. Roentgenol., April 1, 2009; 192(4): W156 - W160. [Abstract] [Full Text] [PDF]

				A. M. Scott, D. H. Gunawardana, D. Bartholomeusz, J. E. Ramshaw, and P. Lin PET Changes Management and Improves Prognostic Stratification in Patients with Head and Neck Cancer: Results of a Multicenter Prospective Study J. Nucl. Med., October 1, 2008; 49(10): 1593 - 1600. [Abstract] [Full Text] [PDF]

				S. Y. Kim, J.-L. Roh, M. R. Kim, J. S. Kim, S.-H. Choi, S. Y. Nam, S.-w. Lee, and S.-B. Kim Use of 18F-FDG PET for Primary Treatment Strategy in Patients with Squamous Cell Carcinoma of the Oropharynx J. Nucl. Med., May 1, 2007; 48(5): 752 - 757. [Abstract] [Full Text] [PDF]

				J.-L. Roh, C. H. Ryu, S.-H. Choi, J. S. Kim, J. H. Lee, K.-J. Cho, S. Y. Nam, and S. Y. Kim Clinical Utility of 18F-FDG PET for Patients with Salivary Gland Malignancies J. Nucl. Med., February 1, 2007; 48(2): 240 - 246. [Abstract] [Full Text] [PDF]

				L. de Geus-Oei, B Wiering, P. Krabbe, T. Ruers, C. Punt, and W. Oyen FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma Ann. Onc., November 1, 2006; 17(11): 1650 - 1655. [Abstract] [Full Text] [PDF]

				R. Sasaki, R. Komaki, H. Macapinlac, J. Erasmus, P. Allen, K. Forster, J. B. Putnam, R. S. Herbst, C. A. Moran, D. A. Podoloff, et al. [18F]Fluorodeoxyglucose Uptake by Positron Emission Tomography Predicts Outcome of Non-Small-Cell Lung Cancer J. Clin. Oncol., February 20, 2005; 23(6): 1136 - 1143. [Abstract] [Full Text] [PDF]

				D. L. Schwartz, J. Rajendran, B. Yueh, M. D. Coltrera, M. LeBlanc, J. Eary, and K. Krohn FDG-PET Prediction of Head and Neck Squamous Cell Cancer Outcomes Arch Otolaryngol Head Neck Surg, December 1, 2004; 130(12): 1361 - 1367. [Abstract] [Full Text] [PDF]

				H. Schoder, H. W. D. Yeung, M. Gonen, D. Kraus, and S. M. Larson Head and Neck Cancer: Clinical Usefulness and Accuracy of PET/CT Image Fusion Radiology, April 1, 2004; 231(1): 65 - 72. [Abstract] [Full Text] [PDF]

				D. C.P. Cobben, B. F.A.M. van der Laan, B. Maas, W. Vaalburg, A. J.H. Suurmeijer, H. J. Hoekstra, P. L. Jager, and P. H. Elsinga 18F-FLT PET for Visualization of Laryngeal Cancer: Comparison with 18F-FDG PET J. Nucl. Med., February 1, 2004; 45(2): 226 - 231. [Abstract] [Full Text] [PDF]

				L. Kostakoglu and S. J. Goldsmith PET in the Assessment of Therapy Response in Patients with Carcinoma of the Head and Neck and of the Esophagus J. Nucl. Med., January 1, 2004; 45(1): 56 - 68. [Abstract] [Full Text] [PDF]

				J. W. Friedberg and V. Chengazi PET Scans in the Staging of Lymphoma: Current Status Oncologist, October 1, 2003; 8(5): 438 - 447. [Abstract] [Full Text] [PDF]